Adhera Therapeutics, Inc.
ATRXHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $252,000 | $76,186 | — |
| Operating income | −$1.6M | −$674,000 | −$2.0M | −$11.3M | −$15.8M | −$6.1M |
| Net income | −$2.1M | −$6.4M | −$3.8M | −$12.0M | −$16.8M | −$6.2M |
| Total assets | $79,000 | $196,000 | $1,000 | $420,000 | $5.1M | $6.2M |
| Total liabilities | $22.3M | $25.3M | $14.8M | — | — | — |
| Equity | −$22.2M | −$25.1M | −$14.7M | −$9.9M | $2.9M | $448,243 |
| EPS (diluted) | $-1.18 | $-12.84 | — | $-1.24 | $-1.64 | — |
| Shares out. | 17.3M | 11.6M | 10.9M | 10.8M | 10.5M | 89.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- 9.5%
- Return on assets
- −2675.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 28183.5%
- Debt / equity
- —
- Book value / share
- $-1.28
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -4281.57distress
- Accruals / assets
- −884.8%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- PRESTALIAJan 21, 2015
Material events
SEC Form 8-K · most recent- Terminated a material agreementJan 18, 2024
- Director / officer changeJan 16, 2024
- Entered a material agreementNov 29, 2023
- Regulation FD disclosureOct 12, 2023
- Entered a material agreement · Unregistered equity saleJun 29, 2023
- Entered a material agreement · Unregistered equity saleMay 5, 2023
- Entered a material agreement · Unregistered equity saleMay 4, 2023
- Entered a material agreement · Unregistered equity saleMar 8, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.